Consensus Statement of the Malignant Hyperthermia Association of the United States on Unresolved Clinical Questions Concerning the Management of Patients With Malignant Hyperthermia

Ronald S. Litman, Victoria I. Smith, Marilyn Green Larach, Lena Mayes, Mohanad Shukry, Mary C. Theroux, Stacey Watt, Cynthia A. Wong

Research output: Contribution to journalArticle

Abstract

At a recent consensus conference, the Malignant Hyperthermia Association of the United States addressed 6 important and unresolved clinical questions concerning the optimal management of patients with malignant hyperthermia (MH) susceptibility or acute MH. They include: (1) How much dantrolene should be available in facilities where volatile agents are not available or administered, and succinylcholine is only stocked on site for emergency purposes? (2) What defines masseter muscle rigidity? What is its relationship to MH, and how should it be managed when it occurs? (3) What is the relationship between MH susceptibility and heat- or exercise-related rhabdomyolysis? (4) What evidence-based interventions should be recommended to alleviate hyperthermia associated with MH? (5) After treatment of acute MH, how much dantrolene should be administered and for how long? What criteria should be used to determine stopping treatment with dantrolene? (6) Can patients with a suspected personal or family history of MH be safely anesthetized before diagnostic testing? This report describes the consensus process and the outcomes for each of the foregoing unanswered clinical questions.

Original languageEnglish (US)
Pages (from-to)652-659
Number of pages8
JournalAnesthesia and analgesia
Volume128
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Malignant Hyperthermia
Consensus
Dantrolene
Muscle Rigidity
Masseter Muscle
Rhabdomyolysis
Succinylcholine
Emergencies
Fever
Hot Temperature
Exercise
Therapeutics

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Consensus Statement of the Malignant Hyperthermia Association of the United States on Unresolved Clinical Questions Concerning the Management of Patients With Malignant Hyperthermia. / Litman, Ronald S.; Smith, Victoria I.; Larach, Marilyn Green; Mayes, Lena; Shukry, Mohanad; Theroux, Mary C.; Watt, Stacey; Wong, Cynthia A.

In: Anesthesia and analgesia, Vol. 128, No. 4, 01.04.2019, p. 652-659.

Research output: Contribution to journalArticle

Litman, Ronald S. ; Smith, Victoria I. ; Larach, Marilyn Green ; Mayes, Lena ; Shukry, Mohanad ; Theroux, Mary C. ; Watt, Stacey ; Wong, Cynthia A. / Consensus Statement of the Malignant Hyperthermia Association of the United States on Unresolved Clinical Questions Concerning the Management of Patients With Malignant Hyperthermia. In: Anesthesia and analgesia. 2019 ; Vol. 128, No. 4. pp. 652-659.
@article{8d794fb7e3cc4cb483c91362d4b54026,
title = "Consensus Statement of the Malignant Hyperthermia Association of the United States on Unresolved Clinical Questions Concerning the Management of Patients With Malignant Hyperthermia",
abstract = "At a recent consensus conference, the Malignant Hyperthermia Association of the United States addressed 6 important and unresolved clinical questions concerning the optimal management of patients with malignant hyperthermia (MH) susceptibility or acute MH. They include: (1) How much dantrolene should be available in facilities where volatile agents are not available or administered, and succinylcholine is only stocked on site for emergency purposes? (2) What defines masseter muscle rigidity? What is its relationship to MH, and how should it be managed when it occurs? (3) What is the relationship between MH susceptibility and heat- or exercise-related rhabdomyolysis? (4) What evidence-based interventions should be recommended to alleviate hyperthermia associated with MH? (5) After treatment of acute MH, how much dantrolene should be administered and for how long? What criteria should be used to determine stopping treatment with dantrolene? (6) Can patients with a suspected personal or family history of MH be safely anesthetized before diagnostic testing? This report describes the consensus process and the outcomes for each of the foregoing unanswered clinical questions.",
author = "Litman, {Ronald S.} and Smith, {Victoria I.} and Larach, {Marilyn Green} and Lena Mayes and Mohanad Shukry and Theroux, {Mary C.} and Stacey Watt and Wong, {Cynthia A.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1213/ANE.0000000000004039",
language = "English (US)",
volume = "128",
pages = "652--659",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Consensus Statement of the Malignant Hyperthermia Association of the United States on Unresolved Clinical Questions Concerning the Management of Patients With Malignant Hyperthermia

AU - Litman, Ronald S.

AU - Smith, Victoria I.

AU - Larach, Marilyn Green

AU - Mayes, Lena

AU - Shukry, Mohanad

AU - Theroux, Mary C.

AU - Watt, Stacey

AU - Wong, Cynthia A.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - At a recent consensus conference, the Malignant Hyperthermia Association of the United States addressed 6 important and unresolved clinical questions concerning the optimal management of patients with malignant hyperthermia (MH) susceptibility or acute MH. They include: (1) How much dantrolene should be available in facilities where volatile agents are not available or administered, and succinylcholine is only stocked on site for emergency purposes? (2) What defines masseter muscle rigidity? What is its relationship to MH, and how should it be managed when it occurs? (3) What is the relationship between MH susceptibility and heat- or exercise-related rhabdomyolysis? (4) What evidence-based interventions should be recommended to alleviate hyperthermia associated with MH? (5) After treatment of acute MH, how much dantrolene should be administered and for how long? What criteria should be used to determine stopping treatment with dantrolene? (6) Can patients with a suspected personal or family history of MH be safely anesthetized before diagnostic testing? This report describes the consensus process and the outcomes for each of the foregoing unanswered clinical questions.

AB - At a recent consensus conference, the Malignant Hyperthermia Association of the United States addressed 6 important and unresolved clinical questions concerning the optimal management of patients with malignant hyperthermia (MH) susceptibility or acute MH. They include: (1) How much dantrolene should be available in facilities where volatile agents are not available or administered, and succinylcholine is only stocked on site for emergency purposes? (2) What defines masseter muscle rigidity? What is its relationship to MH, and how should it be managed when it occurs? (3) What is the relationship between MH susceptibility and heat- or exercise-related rhabdomyolysis? (4) What evidence-based interventions should be recommended to alleviate hyperthermia associated with MH? (5) After treatment of acute MH, how much dantrolene should be administered and for how long? What criteria should be used to determine stopping treatment with dantrolene? (6) Can patients with a suspected personal or family history of MH be safely anesthetized before diagnostic testing? This report describes the consensus process and the outcomes for each of the foregoing unanswered clinical questions.

UR - http://www.scopus.com/inward/record.url?scp=85063284451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063284451&partnerID=8YFLogxK

U2 - 10.1213/ANE.0000000000004039

DO - 10.1213/ANE.0000000000004039

M3 - Article

VL - 128

SP - 652

EP - 659

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 4

ER -